Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
Wendy Osborne(Newcastle upon Tyne Hospitals NHS Foundation Trust), Kirit M. Ardeshna(UCL Biomedical Research Centre), Carlos Bachier, Maud Jonnaert(Autolus (United Kingdom)), Robert W. Chen, Simon Thomas(Autolus (United Kingdom)), Eleni Tholouli(Manchester Royal Infirmary), Maria A. V. Marzolini(The London College), Muhammad Al‐Hajj(GlaxoSmithKline (United States)), Nushmia Z. Khokhar(Autolus (United Kingdom)), Michael Zhang(Stanford Medicine), Peter A. McSweeney(Mesoblast (United States)), Vijay Gopal Reddy Peddareddigari(GlaxoSmithKline (United States)), Martin Pulé(Autolus (United Kingdom)), David Irvine(NHS Greater Glasgow and Clyde), Aravind Ramakrishnan(Fred Hutch Cancer Center)
Cited by 45
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k